Research ArticleClinical Investigation
Open Access

The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer

Jan Taprogge, Carla Abreu, Siraj Yusuf, Gemma Ainsworth, Rachel H. Phillip, Jonathan I. Gear, Rebecca Gregory, Francesca Leek, Iain Murray, Amy B. Coulson, Sarah R. Brown, Yong Du, Kate Newbold, Jonathan Wadsley and Glenn D. Flux
Journal of Nuclear Medicine July 2023, 64 (7) 1125-1130; DOI: https://doi.org/10.2967/jnumed.122.264913

Abstract

Radioactive iodine is well established as a successful treatment for differentiated thyroid cancer (DTC), although around 15% of patients have local recurrence or develop distant metastases and may become refractory to radioactive iodine (RAI). A personalized approach to treatment, based on the absorbed radiation doses delivered and using treatments to enhance RAI uptake, has not yet been developed. Methods: We performed a multicenter clinical trial to investigate the role of selumetinib, which modulates the expression of the sodium iodide symporter, and hence iodine uptake, in the treatment of RAI-refractory DTC. The iodine uptake before and after selumetinib was quantified to assess the effect of selumetinib. The range of absorbed doses delivered to metastatic disease was calculated from pre- and posttherapy imaging, and the predictive accuracy of a theranostic approach to enable personalized treatment planning was investigated. Results: Significant inter- and intrapatient variability was observed with respect to the uptake of RAI and the effect of selumetinib. The absorbed doses delivered to metastatic lesions ranged from less than 1 Gy to 1,170 Gy. A strong positive correlation was found between the absorbed doses predicted from pretherapy imaging and those measured after therapy (r = 0.93, P < 0.001). Conclusion: The variation in outcomes from RAI therapy of DTC may be explained, among other factors, by the range of absorbed doses delivered. The ability to assess the effect of treatments that modulate RAI uptake, and to estimate the absorbed doses at therapy, introduces the potential for patient stratification using a theranostic approach. Patient-specific absorbed dose planning might be the key to more successful treatment of advanced DTC.

Differentiated thyroid cancer (DTC) has been treated with radioactive iodine (RAI) for over 80 y (1). More than 580,000 new DTC cases were estimated worldwide for 2020 (2). Although 84% of patients survive for 10 y or more (3), over 15% of patients have local recurrence or develop distant metastases, and 5%–10% eventually become RAI-refractory (4,5). This status carries a poor prognosis with a median overall survival of 3–5 y. Treatment with lithium carbonate, retinoic acid, or histone deacetylase inhibitors has been attempted to resensitize disease to RAI treatment, but no significant clinical benefit has been demonstrated (3,4).

Initial results have shown that mitogen-activated protein kinase/extracellular-signal–regulated kinase pathway inhibitors such as the mitogen-activated protein kinase inhibitor selumetinib (ARRY-1428860) might be used to increase sodium iodide symporter expression and restore or enhance uptake of RAI (6–8). Further benefit may be gained from a theranostic approach (9), which offers the possibility of personalized treatments by combining therapeutics and diagnostics. In the case of RAI for DTC, the widely available imaging isotope 123I-NaI may be used to guide treatment with 131I-NaI and to predict the absorbed doses delivered to lesions and to healthy organs (10,11).

Here, we report the imaging and dosimetry results from a phase 2 trial (SEL-I-METRY, EudraCT no. 2015-002269-47) to resensitize RAI-refractory DTC to further RAI therapy (12,13). The aims of this aspect of the trial were to establish the quantitative increase in RAI uptake due to selumetinib and the range of absorbed doses delivered to metastatic disease from fixed levels of administered activity. In addition, we aimed to determine the accuracy with which the absorbed doses delivered at therapy may be predicted from pretherapy diagnostic studies and to establish the percentage of lesions responding to treatment.

MATERIALS AND METHODS

Study Design

Patient inclusion and exclusion criteria are provided in Supplemental Table 1 (supplemental materials are available at http://jnm.snmjournals.org). Iodine-refractory disease was defined as one or more lesions with no measurable iodine uptake or an iodine-avid lesion that progressed within 12 mo of RAI. An exploratory endpoint of the SEL-I-METRY trial was to assess the feasibility of quantitative imaging and SPECT/CT-based lesion dosimetry to personalize treatment for patients with advanced DTC.

Participants received 75 mg of selumetinib orally twice daily for 4 wk (Fig. 1). Pre- and postselumetinib quantitative 123I-NaI SPECT/CT and whole-body scans were used to predict the increase in 131I-NaI uptake for subsequent treatment after the initial 4 wk of selumetinib. Patients with an increase in 123I-NaI uptake of more than 30% after selumetinib in at least one lesion went on to receive RAI therapy with a fixed activity of 5.5 GBq of 131I-NaI (13). Patients continued receiving selumetinib until the 131I-NaI therapy (maximum, 18 d) during the 123I-NaI scan review.

FIGURE 1.
FIGURE 1.

SEL-I-METRY imaging schedule consisting of 24-h whole-body and SPECT 123I-NaI scans before selumetinib, 24-h whole-body and SPECT 123I-NaI scans after selumetinib, up to 4 additional dosimetry SPECT/CT 123I-NaI scans after selumetinib, and up to 4 dosimetry SPECT/CT scans after treatment with 5.5 GBq of 131I-NaI. rhTSH = recombinant human thyroid-stimulating hormone; WB = whole body.

For patients eligible for therapy, 123I-NaI dosimetry was performed after the 4 wk of selumetinib administration (referred to here as pretherapy dosimetry) and lesional dosimetry was performed after 131I-NaI therapy (referred to here as posttherapy dosimetry). Pretherapy dosimetry consisted of up to 5 SPECT/CT scans (at 5, 24, 30, 48, and 72 h) after administration of 370 MBq of 123I-NaI. After 131I-NaI therapy, SPECT/CT was performed at 24, 48, 72, and 144 h (Fig. 1). Recombinant human thyroid-stimulating hormone stimulation was administered before 123I-NaI and 131I-NaI. The imaging and reconstruction protocols are provided in Supplemental Tables 2 and 3.

The study was approved by East Midlands, the Leicester South Research Ethics Committee (15/EM/0455), the institutional review boards of participating centers, and the Medicines and Health Care Products Regulatory Agency. All patients provided written informed consent before trial registration.

Quantitative Imaging to Assess Effect of Selumetinib

γ-cameras at participating centers were configured for quantitative imaging including the determination of calibration factors for 123I-NaI and 131I-NaI and dead-time correction factors for 131I-NaI (14). Anatomic lesion volumes were outlined by a trained radiologist on each of the CT components of up to 5 postselumetinib 123I-NaI SPECT/CT scans. Lesions were excluded from the analysis if the largest diameter was smaller than 10 mm. Oversized volumes of interest, encompassing all activity visible within the lesions, were delineated to determine activity retention in all 123I-NaI and 131I-NaI SPECT/CT images. This approach was used to minimize problems arising from breathing motion and partial-volume effects and, therefore, allows for dosimetry estimates of small lesions.

The effect of selumetinib was assessed by calculating the absolute and relative differences in 131I-NaI lesion uptake during therapy, as predicted from the pre- and postselumetinib 123I-NaI images. These were converted to predictions of 131I-NaI uptake during therapy, taking into account the differences in physical half-lives and administered activities.

Predictive Accuracy of Pretherapy Dosimetry and Treatment Planning

Pretherapy dosimetry was performed to predict lesional absorbed doses during 131I-NaI therapy, taking into account the differences in physical half-life and injected activities, to investigate the potential of personalized treatment planning in this cohort. Dosimetry was performed according to the MIRD formalism (15) using mass-adjusted S values and taking into account only self-dose (16). Uncertainties regarding absorbed doses were estimated according to the guidance of the European Association of Nuclear Medicine (17).

The predictive accuracy of the pretherapy dosimetry was assessed by calculating the absolute and relative differences between the absorbed doses predicted before therapy and those measured after therapy.

Lesion Response Assessment

Response after RAI treatment was assessed using RECIST (18). The analysis was performed on a lesion-by-lesion basis between the baseline CT scan and the latest follow-up CT scan (maximum, 12 mo) after RAI treatment. Complete response (CR) was defined as lesion disappearance. Partial response (PR) was a decrease in lesion size by at least 30% (longest axis, in mm). Progressive disease was an increase in lesion size by at least 20% (longest axis, in mm). Stable disease was a case with no CR, PR, or progressive disease. Overall response was observation of either CR or PR, whereas clinical benefit was achievement of CR, PR, or stable disease.

Statistical Analysis

The Kruskal–Wallis test was used to assess whether relative changes in quantitative lesional uptake before and after selumetinib treatment significantly differed between patients. The relationship between relative changes in quantitative uptake before and after selumetinib treatment and baseline uptake was assessed using the Spearman rank correlation coefficient. The relationship between absorbed doses from pretherapy and posttherapy dosimetry was assessed using Pearson product-moment correlation coefficients. To account for the possibility of multiple, nonindependent lesions within a single patient, all correlation coefficients were calculated on group-mean–centered data.

The relationships between postselumetinib uptake and absorbed doses, and among the baseline data, biomarker, and selumetinib treatment parameters, were explored. A multilevel modeling approach was used to account for the nested data structure, incorporating random effects with respect to each patient. Lesional variables (baseline CT lesion size) were explored as fixed effects within the model. Patient-level variables (cancer subtype, sum of CT lesion size, thyroglobulin, and total selumetinib dose) were explored as random effects in the model. All models were adjusted for preselumetinib lesion uptake or pretherapy predicted absorbed doses, respectively, as a fixed effect. A forward selection approach with χ2 testing was used to decide which variables to include in the model. χ2 tests were used to test the difference between the nested models and determine whether inclusion of a variable improved the model fit.

The association between treatment success and quantitative absorbed doses from pre- and postselumetinib 123I-NaI and 131I-NaI imaging was investigated using univariate logistic regression modeling. Additionally, receiver-operating-curve analysis of the data was explored to establish a threshold absorbed dose for overall response rate and clinical benefit rate, using cutoffs at the median, one-third and two-thirds quantiles.

All statistical tests were exploratory because the trial was not formally powered to detect statistically significant effects on the dosimetry endpoints. Testing was performed at the 2-sided 5% significance level and did not account for multiple testing. Statistical analysis was performed using R, version 4.0.2 or later versions, and the Kruskal–Wallis test was performed using GraphPad Prism, version 9.3.1 (GraphPad Software), for Microsoft Windows.

RESULTS

Thirty RAI-refractory DTC patients were recruited to SEL-I-METRY, of whom 28 received selumetinib treatment. After 4 wk of selumetinib, 9 patients (Table 1) demonstrated an increase in 123I-NaI uptake of 30% or more (Fig. 2) and were administered RAI treatment after a median of 12.5 d (range, 2–15 d). During this time, the patients continued to take selumetinib. Within these 9 patients, 39 lesions were identified. Median lesion volume was 2.6 cm3 (minimum, 0.3 cm3; 25th percentile, 0.7 cm3; 75th percentile, 9.6 cm3; maximum, 43.1 cm3). Eighteen lesions were in the lungs, 14 in bone, and 7 in soft tissues (4 in lymph nodes and 3 in the area of the thyroid bed or the neck).

View this table:
TABLE 1.

Patient Characteristics

FIGURE 2.
FIGURE 2.

Example of whole-body planar scans at 24 h after 123I-NaI administration at baseline, before selumetinib was administered (A), and after 4 wk of treatment with selumetinib (B).

Quantitative Imaging to Assess Effect of Selumetinib

Quantitative SPECT before and after treatment with selumetinib was used to assess the effect on RAI uptake. Two lesions were excluded from this analysis because they were not included in the range of the preselumetinib scan. The median predicted 131I-NaI uptake per lesion volume (MBq/cm3) at 24 h in 37 lesions before and after selumetinib was 0.2 MBq/cm3 (range, 0.001–11.5 MBq/cm3) and 2.1 MBq (range, 0.01–175.4 MBq/cm3), respectively. The median absolute change (predicted uptake after selumetinib minus predicted uptake before selumetinib) and the median relative change (predicted uptake after selumetinib divided by uptake before selumetinib) were 1.9 MBq/cm3 (range, −0.4 to 174.9 MBq/cm3) and 16.7 (range, 0.7–819.1), respectively. Figure 3 shows the relative change in predicted 131I-NaI uptake. The absolute and relative changes in uptake are presented in Figures 4 and 5, respectively, with respect to the baseline uptake.

FIGURE 3.
FIGURE 3.

Relative change in predicted 131I-NaI uptake after treatment with selumetinib with respect to uptake before selumetinib administration. Relative increase in uptake is shown for 9 patients who progressed to RAI therapy. P = patient.

FIGURE 4.
FIGURE 4.

Uptake of 131I-NaI before and after treatment with selumetinib. Solid lines represent relative increase in uptake by factors of 1, 10, and 100, respectively, to illustrate relative effect of selumetinib in individual patients and lesions. P = patient.

FIGURE 5.
FIGURE 5.

Relative increase in 131I-NaI uptake after treatment, with selumetinib plotted against baseline uptake of 131I-NaI before treatment. P = patient.

A large inter- and intrapatient variability was observed for the relative change in uptake on a lesional basis. A Kruskal–Wallis test showed that the relative increase in uptake significantly differed between patients (H(8) = 22.48, P = 0.004). There was a weak, positive correlation between the group-mean–centered data of the relative uptake change and the baseline uptake before selumetinib (Supplemental Fig. 1), r(37) = 0.011; however, the relationship was not significant (P = 0.946).

A multilevel modeling approach was used to assess the relationships between postselumetinib uptake, adjusted for preselumetinib lesion uptake, and baseline data, biomarkers, and selumetinib treatment parameters. No variables of interest improved the multilevel model fit over the null model according to the χ2 difference tests, with many models demonstrating singular fit, likely caused by the small sample size’s being unable to support the complexity of the modeling approach. The intraclass correlation coefficient was calculated as 0.093 for patients, indicating large variability.

Predictive Accuracy of Pretherapy Dosimetry

To assess the feasibility of applying theranostic and dosimetry-based treatment planning in this patient cohort, pre- and posttherapy dosimetry was performed to assess the absorbed doses delivered to the lesions and to investigate whether pretherapy imaging can be used for treatment planning. All 39 lesions were evaluated for dosimetry. The median predicted absorbed doses from pretherapy and posttherapy dosimetry were 17.2 Gy (range, 0.1–1,292.1 Gy) and 10.4 Gy (range, 0.3–1,169.9 Gy), respectively. The median relative percentage difference between pretherapy and posttherapy dosimetry was −33% (range, −98% to 764%).

Comparison of predicted absorbed doses before RAI therapy and measured absorbed doses after RAI therapy are shown in Figure 6, illustrating the wide range of absorbed doses delivered. Pearson product-moment correlation analysis of the group-mean–centered data (Supplemental Fig. 2) resulted in a strong positive correlation between the predicted absorbed doses from pretherapy dosimetry and posttherapy dosimetry, r (37) = 0.93, P < 0.001. Figure 7 shows a Bland–Altman plot of the difference between predicted and measured absorbed doses. The estimated bias was 37.0 Gy (SD, 71.9 Gy), illustrating that predicted absorbed doses were higher than delivered absorbed doses. Supplemental Figures 3 and 4 show Bland–Altman plots of the 24-h uptake and the retention half-lives, respectively, comparing the predicted values using pretherapy dosimetry and the values measured after therapy.

FIGURE 6.
FIGURE 6.

Comparison of absorbed doses for each lesion as predicted from pretherapy dosimetry and measured from posttherapy dosimetry.

FIGURE 7.
FIGURE 7.

Bland–Altman plot for comparison of absorbed doses predicted and measured for each lesion, showing difference of predicted absorbed doses minus actual delivered absorbed doses.

A multilevel modeling approach was used to assess the relationships between posttherapy absorbed doses, adjusted for pretherapy predicted absorbed doses, and baseline data, biomarkers, and selumetinib treatment parameters. No variables of interest improved the multilevel model fit over the null model according to the χ2 difference tests, again with many models demonstrating singular fit. The intraclass correlation coefficient was calculated as 0.062 for patients.

Lesion Response Analysis

Follow-up CT scans were collected for 7 patients (last follow-up: at 3 mo in 1 patient, 6 mo in 1 patient, 9 mo in 1 patient, and 12 mo in 4 patients), with a total of 24 lesions included in the analysis. Response was assessed using RECIST (18) but on an individual-lesion basis by comparing the baseline CT scan with the latest follow-up scan for each patient. Overall response was defined as either CR (disappearance of the lesion) or PR (≥30% decrease in lesion size as defined by the longest axis, in mm). Clinical benefit was taken to be CR, PR, or stable disease (<30% decrease or increase in lesion size). Overall response and clinical benefit were observed in 13% (3/24) and 83% (20/24) of lesions, respectively.

Univariate logistic regression modeling was used to assess the association between quantitative absorbed doses from pre- and postselumetinib therapy imaging and treatment success. The logistic models demonstrated poor fit due to small sample size, were highly influenced by outliers in the data, and are therefore not presented. Receiver-operating-curve analysis was also limited by the small sample size, and a threshold absorbed dose could not established.

DISCUSSION

Quantitative 123I-NaI imaging has shown great potential to assess whether further 131I-NaI treatment is warranted after attempted resensitization of RAI-refractory DTC with selumetinib. Significant inter- and intrapatient variability in the relative change in RAI uptake after selumetinib treatment was found in the present cohort. This variability suggests that, to fulfil the justification principle, patient-specific uptake changes should be assessed before RAI therapy proceeds. Furthermore, the RAI concentration within lesions before and after selumetinib treatment markedly differed between and within patients. No patient- or lesion-specific biomarkers were found to be predictive of uptake. Results of studies by Ho et al. suggest that a biomarker-directed strategy may be required, as redifferentiation using selumetinib in BRAFV600E-mutant patients appeared to be less successful (7,19).

The relative change in uptake did not correlate with baseline uptake, suggesting that selumetinib might also be effective in nonrefractory patients, who still have a degree of iodine uptake in lesions before starting treatment. Ho et al. (19) used selumetinib plus RAI therapy in a phase 3 randomized clinical trial on the adjuvant treatment of high-risk, resected DTC patients but could not show a statistically significant difference in complete remission when compared with RAI therapy alone. Further investigations are warranted on the use of selumetinib or other related drugs to improve the outcome in cohorts of advanced-DTC patients at risk of becoming RAI-refractory.

The wide range of RAI uptake observed is also reflected by the wide range of absorbed dose delivered to lesions from a fixed 5.5-GBq administration to patients with advanced DTC. This administration is considered standard practice in the United Kingdom and in line with national guidelines and was therefore used in the current study (20). The wide range agrees with results presented previously (21,22) and might explain the variations in outcome observed among patients. Personalized treatment planning based on the absorbed doses delivered could, therefore, potentially be warranted in this cohort.

The results suggest that personalized treatment planning using pretherapy 123I-NaI is feasible. Although the absolute accuracy decreases for absorbed doses higher than 50 Gy, pretherapy dosimetry correlated fairly well with posttreatment dosimetry. The average difference of −33% may be due to differences in imaging schedules, the possibility of a stunning effect of 123I-NaI or self-stunning of 131I-NaI (23,24,25), a delayed action of the selumetinib during the time before therapy, alterations of biokinetics due to prior administration of recombinant human thyroid-stimulating hormone (26), saturation of receptors, or the continued use of selumetinib before RAI therapy. The last of these possibilities has not yet been studied. To our knowledge, this is the first time that 123I-NaI pretherapy dosimetry has been shown to be indicative of the absorbed doses delivered from treatment in metastatic DTC patients. This result might have wide implications for molecular radiotherapy, by allowing for personalized treatment planning in combination with dosimetric methods to assess absorbed doses to organs at risk, such as whole-body and bone marrow dosimetry (27).

The large uncertainties in absorbed doses, brought about by the use of oversized volumes of interest, reflect the volume estimate uncertainties for small lesions and the significantly shorter half-life of 123I-NaI (28). Uncertainties are potentially smaller with 124I-NaI pretherapy dosimetry, which was not available for this study. The longer physical half-life of 124I-NaI than of 123I-NaI would allow for more accurate determination of the retention half-lives. 123I-NaI pretherapy dosimetry potentially overestimates the retention half-life (Supplemental Fig. 3) and, therefore, the absorbed dose delivered.

The present analysis has some limitations. The trial was not designed to have sufficient power to detect statistically significant effects on the dosimetry endpoints, and statistical testing did not account for multiple testing. The relatively small number of patients undergoing both pre- and posttherapy dosimetry is a limiting factor, and the statistical analysis should be considered exploratory. When feasible, future studies should be sufficiently powered to detect statistically significant effects and to identify key parameters affecting both the response to treatments before RAI therapy and the absorbed doses delivered. Additionally, since these types of data have a nested structure of lesions within patients, careful consideration should be given to the design of trials aiming to capture these data. Such a design will aid in avoiding or mitigating potential issues that may arise when using a multilevel modeling approach, such as the issues with model singularity encountered here. Follow-up analysis was limited by the short follow-up time, leading to inconclusive results with respect to the absorbed dose relationship due to a poor model fit. Response measurements of bone lesions using RECIST are considered difficult but can be performed for osteolytic lesions, the predominant type in thyroid cancer. Nevertheless, the lack of an absorbed dose relationship potentially reflects that 14 of the 39 lesions were found in bone. Similarly, an absorbed dose threshold could not be identified. Most absorbed doses delivered were estimated to be lower than the proposed absorbed dose thresholds for soft-tissue (29) and bone metastases (30), as is in line with the low overall response rate of 13%.

Absorbed dose–response relationships for advanced DTC (30) should be confirmed in multicenter clinical trials. Together with the results presented here, these future results would facilitate personalized treatment planning of RAI administrations.

CONCLUSION

Quantitative SPECT/CT has shown large inter- and intrapatient variability in the effect of selumetinib on increasing the lesional RAI uptake in advanced RAI-refractory DTC. In addition, a large range of RAI uptake concentrations was observed in lesions at baseline. The absorbed doses delivered at therapy in this cohort can be estimated from a pretherapy dosimetry study. These findings suggest that future studies of redifferentiation therapy should use the combination of pretherapy quantitative imaging (to assess the effect of treatments to enhance RAI uptake) and dosimetry (to plan the activity of RAI administered to patients) to ensure that those patients achieving increased iodine uptake obtain maximum benefit from subsequent therapy. Our findings also likely have implications for the personalized treatment planning of patients with iodine-sensitive DTC.

DISCLOSURE

Financial support was received from Cancer Research U.K. (CRUK) (CRUK reference CRUK/14/041), AstraZeneca U.K. Limited, the NIHR Biomedical Research Centre at RMH/ICR, and the National Institute for Health Research (NIHR). Sanofi Genzyme provided recombinant human thyroid-stimulating hormone. Sarah Brown, Glenn Flux, Jonathan Wadsley, Jan Taprogge, Iain Murray, Jonathan Gear, and Carla Abreu report funding or provision of study materials from CRUK, AstraZeneca, and Sanofi Genzyme during the conduct of the study. Jan Taprogge, Carla Abreu, Jonathan Gear, Iain Murray, and Glenn Flux report funding from the National Health Service to the NIHR Biomedical Research Centre at the Royal Marsden and the ICR and grants from Euratom research and training program 2014–2018 and the NIHR and NIHR Royal Marsden Clinical Research Facility. Jonathan Gear reports personal fees and honoraria from the European Association of Nuclear Medicine. Jonathan Wadsley reports personal fees and honoraria from Lilly, Eisai, Novartis, AAA, Bayer, Ipsen, and Roche. Amy Coulson reports grants and nonfinancial support from BMS/Celgene, Merck Sharpe & Dohme, Amgen, and Takeda. Sanofi Genzyme provided recombinant human thyroid-stimulating hormone. The research was developed with support from NCRI CTRad. NHS funding was provided to the NIHR Biomedical Research Centre at the Royal Marsden and the ICR. The RTTQA group is funded by the NIHR. We acknowledge infrastructure support from NIHR Royal Marsden Clinical Research Facility funding. This report is independent research funded by the NIHR. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. No other potential conflict of interest relevant to this article was reported.

KEY POINTS

QUESTION: Can quantitative imaging and SPECT/CT-based lesional dosimetry be used to personalize RAI treatment for advanced thyroid cancer, which currently has a poor prognosis?

PERTINENT FINDINGS: Pretherapy imaging was found to be a powerful tool to assist with the stratification of patients before further RAI therapy, and a strong positive correlation was found between pre- and posttherapy absorbed doses, indicating the suitability of pretherapy dosimetry for treatment planning.

IMPLICATIONS FOR PATIENT CARE: Pretherapy quantitative imaging and dosimetry in RAI therapy for advanced thyroid cancer has the potential to inform treatment planning for individual patients and to alter patient management.

ACKNOWLEDGMENTS

We are deeply indebted to the participants and their families and carers. We are grateful to the SEL-I-METRY teams at the participating hospitals and the Trial Steering Committee and Data Monitoring and Ethics Committee members, without whom this trial would not have been possible.

Footnotes

  • Published online Apr. 28, 2023.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

REFERENCES

  1. 1.↵
    1. Hertz S,
    2. Roberts A
    . Radioactive iodine in the study of thyroid physiology: VII. The use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 1946;131:81–86.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Pizzato M,
    2. Li M,
    3. Vignat J,
    4. et al
    . The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10:264–272.
    OpenUrl
  3. 3.↵
    1. Schlumberger M,
    2. Brose M,
    3. Elisei R,
    4. et al
    . Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2:356–358.
    OpenUrl
  4. 4.↵
    1. Jin Y,
    2. Van Nostrand D,
    3. Cheng L,
    4. Liu M,
    5. Chen L
    . Radioiodine refractory differentiated thyroid cancer. Crit Rev Oncol Hematol. 2018;125:111–120.
    OpenUrl
  5. 5.↵
    1. Durante C,
    2. Haddy N,
    3. Baudin E,
    4. et al
    . Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–2899.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Chakravarty D,
    2. Santos E,
    3. Ryder M,
    4. et al
    . Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121:4700–4711.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Ho AL,
    2. Grewal RK,
    3. Leboeuf R,
    4. et al
    . Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623–632.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Rothenberg SM,
    2. McFadden DG,
    3. Palmer EL,
    4. Daniels GH,
    5. Wirth LJ
    . Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015;21:1028–1035.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Arnold C
    . Theranostics could be big business in precision oncology. Nat Med. 2022;28:606–608.
    OpenUrl
  10. 10.↵
    1. Van Nostrand D,
    2. Aiken M,
    3. Atkins F,
    4. et al
    . The utility of radioiodine scans prior to iodine-131 ablation in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:849–855.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Brans B,
    2. Bodei L,
    3. Giammarile F,
    4. et al
    . Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray.” Eur J Nucl Med Mol Imaging. 2007;34:772–786.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Wadsley J,
    2. Gregory R,
    3. Flux G,
    4. et al
    . SELIMETRY: a multicentre I-131 dosimetry trial—a clinical perspective. Br J Radiol. 2017;90:20160637.
    OpenUrl
  13. 13.↵
    1. Brown SR,
    2. Hall A,
    3. Buckley HL,
    4. et al
    . Investigating the potential clinical benefit of selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer. 2019;19:582.
    OpenUrl
  14. 14.↵
    1. Gregory RA,
    2. Murray I,
    3. Gear J,
    4. et al
    . Standardised quantitative radioiodine SPECT/CT imaging for multicentre dosimetry trials in molecular radiotherapy. Phys Med Biol. 2019;64:245013.
    OpenUrl
  15. 15.↵
    1. Bolch WE,
    2. Eckerman KF,
    3. Sgouros G,
    4. Thomas SR
    . MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry—standardization of nomenclature. J Nucl Med. 2009;50:477–484.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Stabin MG,
    2. Siegel JA
    . Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Gear JI,
    2. Cox MG,
    3. Gustafsson J,
    4. et al
    . EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45:2456–2474.
    OpenUrl
  18. 18.↵
    1. Eisenhauer EA,
    2. Therasse P,
    3. Bogaerts J,
    4. et al
    . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Ho AL,
    2. Dedecjus M,
    3. Wirth LJ,
    4. et al
    . Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase III, randomized, placebo-controlled trial (ASTRA). J Clin Oncol. 2022;40:1870–1878.
    OpenUrl
  20. 20.↵
    1. Wadsley J,
    2. Armstrong N,
    3. Bassett-Smith V,
    4. et al
    . Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer in the UK. Clin Oncol (R Coll Radiol). 2023;35:42–56.
    OpenUrl
  21. 21.↵
    1. de Keizer B,
    2. Brans B,
    3. Hoekstra A,
    4. et al
    . Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging. 2003;30:367–373.
    OpenUrlPubMed
  22. 22.↵
    1. Sun F,
    2. Gerrard GE,
    3. Roberts JK,
    4. et al
    . Ten year experience of radioiodine dosimetry: is it useful in the management of metastatic differentiated thyroid cancer? Clin Oncol (R Coll Radiol). 2017;29:310–315.
    OpenUrl
  23. 23.↵
    1. Lassmann M,
    2. Luster M,
    3. Hänscheid H,
    4. Reiners C
    . Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45:619–625.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. McDougall IR,
    2. Iagaru A
    . Thyroid stunning: fact or fiction? Semin Nucl Med. 2011;41:105–112.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Canzi C,
    2. Zito F,
    3. Voltini F,
    4. Reschini E,
    5. Gerundini P
    . Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. Med Phys. 2006;33:2860–2867.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Hänscheid H,
    2. Lassmann M,
    3. Luster M,
    4. et al
    . Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–654.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Lassmann M,
    2. Hänscheid H,
    3. Chiesa C,
    4. et al
    . EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35:1405–1412.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Flux GD,
    2. Guy MJ,
    3. Beddows R,
    4. Pryor M,
    5. Flower MA
    . Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol. 2002;47:3211–3223.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Maxon HR,
    2. Thomas SR,
    3. Hertzberg VS,
    4. et al
    . Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–941.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Jentzen W,
    2. Verschure F,
    3. van Zon A,
    4. et al
    . 124I-PET assessment of response of bone metastases to initial radioiodine treatment of differentiated thyroid cancer. J Nucl Med. 2016;57:1499–1504.
    OpenUrlAbstract/FREE Full Text
  • Received for publication September 14, 2022.
  • Revision received February 7, 2023.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords